Organisation paid for research Program year 2025 Source: CMS Open Payments

First Oc Dermatology

Neither a doctor nor a teaching hospital

Research payments

$6,235,317

1,235 payments

Through program year 2025, First Oc Dermatology is reported as receiving $6,235,317 in research payments, across 1,235 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$519,742	188
2024	Research	$936,658	298
2023	Research	$836,812	306
2022	Research	$946,253	144
2021	Research	$1,544,281	155
2020	Research	$1,002,149	120
2019	Research	$449,422	24

Breakdown

Who paid Research payments · program years 2019–2025

Amgen Inc. $2,028,513 83 payments
Incyte Corporation $1,608,991 737 payments
Novartis Pharmaceuticals Corporation $890,076 18 payments
AbbVie, Inc. $510,651 108 payments
E.R. Squibb & Sons, L.L.C. $334,384 16 payments
Sun Pharmaceutical Industries Inc. $233,546 177 payments
Bausch Health US, LLC $232,061 5 payments
Celgene Corporation $179,723 7 payments
Arena Pharmaceuticals, Inc. $44,676 21 payments
Kiniksa Pharmaceuticals International, plc $42,214 3 payments

Studies the money was for Research payments · program years 2019–2025

Pediatric Study in Children With Moderate to Severe Plaque Psoriasis $785,915 8 payments
P3 switching study PK; plaque psoriasis $261,616 2 payments
Psor-025/20200063 (Discreet) $233,638 2 payments
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa $227,865 15 payments
PPSO-004/20200057 (SPROUT Rollover) $225,121 2 payments
M16-046 $191,602 18 payments
Brodalumab in Palmoplantar Psoriasis, Evaluating Efficacy and Clinical Photography $181,521 1 payment
Efficacy/Safety Study of Apremilast in Pedi Subjects With Moderate to Severe Plaque PSO (PPSO-003) $166,334 16 payments
Efficacy Safety Study of Apremilast in Subjects With Moderate to Severe Genital Psoriasis(PSOR-025) $162,545 12 payments
ASCEND P3 AD Extension $148,269 2 payments

What the money was spent on Research payments · program years 2019–2025

Other $1,057 14 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.